Journal article
Pharmacogenomics and functional imaging to predict irinotecan pharmacokinetics and pharmacodynamics: the predict IR study
M Michael, W Liauw, SA McLachlan, E Link, A Matera, M Thompson, M Jefford, RJ Hicks, C Cullinane, A Hatzimihalis, IG Campbell, S Rowley, PJ Beale, CS Karapetis, T Price, ME Burge
Cancer Chemotherapy and Pharmacology | SPRINGER | Published : 2021
Abstract
Purpose: Irinotecan (IR) displays significant PK/PD variability. This study evaluated functional hepatic imaging (HNI) and extensive pharmacogenomics (PGs) to explore associations with IR PK and PD (toxicity and response). Methods: Eligible patients (pts) suitable for Irinotecan-based therapy. At baseline: (i) PGs: blood analyzed by the Affymetrix-DMET™-Plus-Array (1936 variants: 1931 single nucleotide polymorphisms [SNPs] and 5 copy number variants in 225 genes, including 47 phase I, 80 phase II enzymes, and membrane transporters) and Sanger sequencing (variants in HNF1A, Topo-1, XRCC1, PARP1, TDP, CDC45L, NKFB1, and MTHFR), (ii) HNI: pts given IV 250 MBq-99mTc-IDA, data derived for hepatic..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
Funded by the Australian National Health and Medical Research Council Grant 628564.